Late effects after hematopoietic stem cell transplantation for (cid:12) -thalassemia major: the French national experience

of males. Female patients who went on to normal puberty after transplant were significantly younger at transplantation than those who experienced delayed puberty (median age 2.5 vs . 8.7 years). Fertility was preserved in 9 of 27 females aged 20 years or older and 2 other patients became pregnant following oocyte donation. In addition to patient’s age and higher serum ferritin levels at transplantation, time elapsed since transplant was significantly associated with decreased height growth in multivariate analysis. Weight growth increased after transplantation particularly in females, 36% of adults being overweight at last evaluation. A comprehensive long-term monitoring, especially of endocrine late effects, is required after hematopoietic stem cell transplantation for thalassemia.

[1]  Y. Lai.  [How I treat thalassemia]. , 2018, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.

[2]  S. Ha,et al.  Endocrine complications in patients with transfusion-dependent thalassaemia after haemopoietic stem cell transplantation , 2018, Bone Marrow Transplantation.

[3]  M. Ayas,et al.  A Multicenter Retrospective Analysis Stressing the Importance of Long-Term Follow-Up after Hematopoietic Cell Transplantation for β-Thalassemia. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  P. Moi,et al.  Long‐term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment , 2017, American journal of hematology.

[5]  A. Miccio,et al.  Gene Therapy for β-Hemoglobinopathies. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  S. Santarone,et al.  Pregnancy outcome following hematopoietic cell transplantation for thalassemia major , 2017, Bone Marrow Transplantation.

[7]  M. Cappellini,et al.  One‐year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation , 2017, Pediatric blood & cancer.

[8]  J. Kurtzberg,et al.  Late Effects after Umbilical Cord Blood Transplantation in Very Young Children after Busulfan-Based, Myeloablative Conditioning. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  E. Angelucci,et al.  Management of iron overload before, during, and after hematopoietic stem cell transplantation for thalassemia major , 2016, Annals of the New York Academy of Sciences.

[10]  F. Locatelli,et al.  Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000–2010 , 2016, Bone Marrow Transplantation.

[11]  B. Andersson,et al.  Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  M. Yesilipek,et al.  Evaluating the Patients with Thalassemia Major for Long-Term Endocrinological Complications After Bone Marrow Transplantation , 2014, Pediatric hematology and oncology.

[13]  P. Auquier,et al.  Health status of childhood leukemia survivors who received hematopoietic cell transplantation after BU or TBI: an LEA study , 2014, Bone Marrow Transplantation.

[14]  C. Carcassi,et al.  Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia. , 2013, Blood.

[15]  R. Elhasid,et al.  Factors Influencing Outcome and Incidence of Late Complications in Children who Underwent Allogeneic Hematopoietic Stem Cell Transplantation for Hemoglobinopathy , 2012, Pediatric hematology and oncology.

[16]  A. Mastronuzzi,et al.  Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. , 2012, Blood.

[17]  E. Angelucci.  Hematopoietic stem cell transplantation in thalassemia. , 2010, Hematology. American Society of Hematology. Education Program.

[18]  B. Pégourié,et al.  Complications and treatment of patients with β-thalassemia in France: results of the National Registry , 2010, Haematologica.

[19]  P. Auquier,et al.  Height growth during adolescence and final height after haematopoietic SCT for childhood acute leukaemia: the impact of a conditioning regimen with BU or TBI , 2009, Bone Marrow Transplantation.

[20]  R. Storb,et al.  Thyroid function following hematopoietic cell transplantation in children: 30 years' experience. , 2009, Blood.

[21]  S. Santarone,et al.  Long‐term results of survival in patients with thalassemia major treated with bone marrow transplantation , 2008, American journal of hematology.

[22]  M. Cazzola,et al.  Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders , 2008, Haematologica.

[23]  S. Homan,et al.  APPLIED MIXED MODELS IN MEDICINE, 2ND ED. , 2007 .

[24]  G. Wong,et al.  GROWTH AND ENDOCRINE FUNCTION FOLLOWING BONE MARROW TRANSPLANTATION FOR THALASSEMIA MAJOR , 2004, Pediatric hematology and oncology.

[25]  V. De Sanctis.  Growth and Puberty and Its Management in Thalassaemia , 2002, Hormone Research in Paediatrics.

[26]  A. Verrotti,et al.  Final height of thalassemic patients who underwent bone marrow transplantation during childhood , 2001, Bone Marrow Transplantation.

[27]  Helen Brown,et al.  Applied Mixed Models in Medicine , 2000, Technometrics.

[28]  C. Cowell,et al.  Growth and endocrine function in children with acute myeloid leukaemia after bone marrow transplantation using busulfan/cyclophosphamide , 2000, Bone Marrow Transplantation.

[29]  G. Lucarelli,et al.  Evaluation of cardiac status in iron‐loaded thalassaemia patients following bone marrow transplantation: improvement in cardiac function during reduction in body iron burden , 1998, British journal of haematology.

[30]  G. Lucarelli,et al.  Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. , 1997, Blood.

[31]  F. Angrilli,et al.  Growth and endocrine function following bone marrow transplantation for thalassemia. , 1995, Bone marrow transplantation.

[32]  M. Andreani,et al.  Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. , 1993, The New England journal of medicine.

[33]  S. Rivkees,et al.  The relationship of gonadal activity and chemotherapy-induced gonadal damage. , 1988, JAMA.

[34]  MARROW TRANSPLANTATION FOR THALASSAEMIA , 1987, The Lancet.

[35]  G. Lucarelli,et al.  MARROW TRANSPLANTATION FOR THALASSAEMIA FOLLOWING BUSULPHAN AND CYCLOPHOSPHAMIDE , 1985, The Lancet.

[36]  M. Sempé,et al.  ["Chronos": analysis of bone maturation by an automated numerical method]. , 1979, Pediatrie.

[37]  T. G. Baker,et al.  A QUANTITATIVE AND CYTOLOGICAL STUDY OF GERM CELLS IN HUMAN OVARIES. , 1964, Proceedings of the Royal Society of London. Series B, Biological sciences.

[38]  S. Salvadori,et al.  Secondary solid cancer following hematopoietic cell transplantation in patients with thalassemia major , 2018, Bone Marrow Transplantation.

[39]  P. Frange,et al.  French multicenter 22-year experience in stem cell transplantation for beta-thalassemia major: lessons and future directions. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[40]  S. Pakakasama,et al.  Gonadal function of beta-thalassemics following stem cell transplantation conditioned with myeloablative and reduced intensity regimens , 2013, Journal of pediatric endocrinology & metabolism : JPEM.

[41]  W. Cho,et al.  Primary ovarian dysfunction after hematopoietic stem cell transplantation during childhood: busulfan-based conditioning is a major concern , 2011, Journal of pediatric endocrinology & metabolism : JPEM.

[42]  V. Kitra,et al.  Gonadal Function of Young Patients with Beta-Thalassemia Following Bone Marrow Transplantation , 2005, Journal of pediatric endocrinology & metabolism : JPEM.

[43]  G. Leverger,et al.  Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.